Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab vs Risankizumab in Active Psoriatic Arthritis
NCT06624228Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2024
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of bimekizumab in psoriatic arthritis (PsA), sponsored by UCB. Started Oct 2024; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06624228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624228.